Evaluation of the Nanosphere Verigene Gram-Positive Blood Culture Assay with VersaTREK Blood Culture System and Assessment of Possible Impact on Selected Patients.

Related Articles

Evaluation of the Nanosphere Verigene Gram-Positive Blood Culture Assay with VersaTREK Blood Culture System and Assessment of Possible Impact on Selected Patients.

J Clin Microbiol. 2013 Sep 18;

Authors: Beal SG, Ciurca J, Smith G, John J, Lee F, Doern CD, Gander RM

Abstract
The Verigene® Gram-Positive Blood Culture (BC-GP) Assay (Nanosphere, Northbrook, IL) is a molecular method for rapid identification of Gram-positive organisms and resistance markers directly from blood culture bottles. A total of 148 VersaTREK REDOX 1 40 mL aerobic bottles demonstrating Gram-positive bacteria were tested. Results were compared with conventional biochemical and MALDI-TOF identification. We isolated the following organisms: MRSA, 24; MSSA, 14; methicillin-resistant S. epidermidis (MRSE), 17; methicillin-susceptible S. epidermidis (MSSE), 9; other coagulase-negative staphylococci, 19; S. salivarius, 5; S. parasanguinis, 2; S. sanguinis, 1; S. cristatus, 1; S. bovis group, 5; S. agalactiae, 9; Streptococcus anginosus group, 1; Streptococcus pneumoniae, 6; vancomycin-resistant E. faecium (VRE FCM), 16; vancomycin-susceptible E. faecalis, 3; Aerococcus viridans, 2; Bacillus, 6; Corynebacterium, 8; Lactobacillus, 2; Micrococcus, 2; Neisseria mucosa, 1; Escherichia coli, 3; C. tropicalis, 1; Propionibacterium, 1; Rothia., 1. Our overall agreement with culture results was 95%. 137 of 138 (99%) monomicrobial cultures were concordant. We tested 9 polymicrobial samples with 33% agreement. Chart review of 31 patients with MRSA, MSSA, or VRE demonstrated that the Nanosphere might have led to more appropriate antibiotic selection an average of 42 hours earlier in these patients. Additionally, contact isolation could have been initiated an average of 37 hours earlier in patients with MRSA or VRE. The BC-GP may have a positive impact on patient care, health-care costs, and antibiotic stewardship.

PMID: 24048531 [PubMed - as supplied by publisher]